Gynecologic cancers affect thousands of women each year, yet many remain difficult to detect in their earliest stages.

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...

As an eager tester of new therapies to reduce her biological age, or how fast she is aging internally, Barnes-Lentz thrives on collecting more data about her health. It’s especially important for her ...

Vague is a word frequently used to describe symptoms of ovarian cancer. However, if there are key and persistent signs that last more than two or three weeks, it likely would be wise to see a ...